StemCell Therapy

Miami, FL (PRWEB) February 11, 2014

Global Stem Cells Group, Bioheart, Inc., and Paul Perito Urology announce plans to launch stem cell clinical trials for treatment of Erectile Dysfunction (ED).

Paul Perito, M.D. of Perito Urology in Coral Gables, Florida and the principal investigator of the trial study, titled, "An Open-label, Non-randomized, Single-center Study to Assess the Safety and Effects of Autologous Adipose-derived Stromal Cells Delivered into the Corpus Cavernosum in Patients with Erectile Dysfunction," aims to assess the safety and efficacy of stem cell implantation therapy in patients with ED.

The cell therapy in this study will be composed of stem cells derived from a patients own adipose (fat) tissue, harvested by syringe liposuction. The adipose stem cells will then be delivered into the corpus cavernosum of the penis.

Clinical trials will be held at Perito Urology, in cooperation with Global Stem Cells Group and Bioheart. Up to 20 patients will be enrolled.

Fort Myers Florida-based Emcyte Corporation, a leading provider of biotechnology products for platelet rich plasma and bone marrow concentrate grafting procedures, will be providing systems and kits to be used in the trial.

To learn more about Global Stem Cells Group's clinical trials, and for investor information, visit the Global Stem Cell Group website, email bnovas(at)regenestem(dot)com, or call 305-224-1858.

About the Global Stem Cell Group:

Global Stem Cells Group, Inc. is the parent company of six wholly owned operating companies dedicated entirely to stem cell research, training, products and solutions. Founded in 2012, the company combines dedicated researchers, physician and patient educators and solution providers with the shared goal of meeting the growing worldwide need for leading edge stem cell treatments and solutions. With a singular focus on this exciting new area of medical research, Global Stem Cells Group and its subsidiaries are uniquely positioned to become global leaders in cellular medicine.

Global Stem Cells Groups corporate mission is to make the promise of stem cell medicine a reality for patients around the world. With each of GSCGs six operating companies focused on a separate research-based mission, the result is a global network of state-of-the-art stem cell treatments.

The rest is here:
Global Stem Cells, Inc., Bioheart, Inc., and Paul Perito Urology Announce Plans to Launch Stem Cell Clinical Trials ...

Cancer researchers led by stem cell scientist Dr. John Dick have discovered a pre-leukemic stem cell that may be the first step in initiating disease and also the culprit that evades therapy and triggers relapse in patients with acute myeloid leukemia (AML).

The research, published online today in Nature is a significant leap in understanding the steps that a normal cell has to go through as it turns into AML, says Dr. Dick, and sets the stage to advance personalized cancer medicine by potentially identifying individuals who might benefit from targeting the pre-leukemic stem cell. AML is an aggressive blood cancer that the new research shows starts in stem cells in the bone marrow. Dr. Dick, a Senior Scientist at Princess Margaret Cancer Centre, University Health Network (UHN), and Professor in the Department of Molecular Genetics, University of Toronto, pioneered the cancer stem cell field by first identifying leukemia stem cells (1994) and colon cancer stem cells (2007).

"Our discovery lays the groundwork to detect and target the pre-leukemic stem cell and thereby potentially stop the disease at a very early stage when it may be more amenable to treatment," says Dr. Dick, who holds a Canada Research Chair in Stem Cell Biology and is also Director of the Cancer Stem Cell Program at the Ontario Institute for Cancer Research (OICR).

"Now we have a potential tool for earlier diagnosis that may allow early intervention before the development of full AML. We can also monitor remission and initiate therapy to target the pre-leukemic stem cell to prevent relapse," he says.

The findings show that in about 25% of AML patients, a mutation in the gene DNMT3a causes pre-leukemic stem cells to develop that function like normal blood stem cells but grow abnormally. These cells survive chemotherapy and can be found in the bone marrow at remission, forming a reservoir of cells that may eventually acquire additional mutations, leading to relapse.

The discovery of pre-leukemic stem cells came out of a large Leukemia Disease Team that Dr. Dick assembled and included oncologists who collected samples for the Princess Margaret Cancer Centre Biobank and genome scientists at the OICR who developed sophisticated targeted sequencing methodology. With this team, it was possible to carry out genomic analysis of more than 100 leukemia genes on many patient samples. The findings also capitalized on data from more than six years of experiments in Dr. Dick's lab involving growing human AML in special mice that do not reject human cells.

"By peering into the black box of how cancer develops during the months and years prior to when it is first diagnosed, we have demonstrated a unique finding. People tend to think relapse after remission means chemotherapy didn't kill all the cancer cells. Our study suggests that in some cases the chemotherapy does, in fact, eradicate AML; what it does not touch are the pre-leukemic stem cells that can trigger another round of AML development and ultimately disease relapse," says Dr. Dick, who anticipates the findings will spawn accelerated drug development to specifically target DNMT3a.

These findings should also provide impetus for researchers to look for pre-cancerous cells in AML patients with other mutations and even in non-blood cancers.

Dr. Dick is also renowned for isolating a human blood stem cell in its purest form (2011) -- as a single stem cell capable of regenerating the entire blood system. He is a Senior Scientist at UHN's McEwen Centre for Regenerative Medicine and co-leader of a Cancer Stem Cell Consortium (CSCC)-funded research project HALT (Highly Active Anti-Leukemia Stem Cell Therapy), which is a partnership between CSCC and the California Institute for Regenerative Medicine.

For more than 20 years, Dr. Dick's research has focused on understanding the cellular processes that maintain tumour growth by investigating the complexities and interplay among genetic and non-genetic determinants of cancer. His research follows on the original 1961 discovery of the blood stem cell by Princess Margaret Cancer Centre (formerly Ontario Cancer Institute) scientists Dr. James Till and the late Dr. Ernest McCulloch, which formed the basis of all current stem cell research.

See the original post:
Cancer Researchers Discover Pre-Leukemic Stem Cell at Root of AML, Relapse

For more information,Please Contact consultant physician Peh Pang Pang CALL +65 9626 6803 NOW + STEM CELL Therapy Blk 342 #02-...

By: Stem Cells

The rest is here:
- Video

VTS 01 1 mpeg4
For more information,Please Contact +65 9626 6803 consultant physician Peh Pang Pang + 96266803 STEM CELL Therapy Bl...

By: Stem Cells

Follow this link:
VTS 01 1 mpeg4 - Video

SCIENCE LAB MOVED TO SPACE, IS IT DUE TO POSSIBLE LIABILITY? STEM CELLS
2-7-14 M2U02582 HEY YOU ALL, DON #39;T WE HAVE ANTI GRAVITY PLACES HERE, UH, HELLO, YES, BUT OH WAIT, WE HAVE TO SPEND MORE OF OUR TAXPAYER MONEY TO SEND A DAMN ...

By: WheepingWillow2

Read the rest here:
SCIENCE LAB MOVED TO SPACE, IS IT DUE TO POSSIBLE LIABILITY? STEM CELLS - Video

ATMI - World Stem Cells Regenerative Medicine Congress 2013

We spoke with some of the sponsors at Europe's largest stem cells and regenerative medicine industry conference. This is a three day congress that stages a s...

We spoke with some of the sponsors at Europe's largest stem cells and regenerative medicine industry conference. This is a three day congress that stages a s...

Why should you attend? Watch the video to find out.

Geoff MacKay, Chair, Alliance for Regenerative Medicine (ARM); President & CEO, Organogenesis Inc. The 2013 Stem Cell Meeting on the Mesa was a three-day conference, held October 14-16 in La Jolla, CA, and aimed at bringing together senior members of the regenerative medicine industry with the scientific research community to advance stem cell science into cures. The meeting featured a nationally recognized Scientific Symposium, attended by leading scientists and researchers, in conjunction with the industry's premier annual Regen Med Partnering Forum. Combined, these meetings attracted over 750 attendees from around the globe, fostering key partnerships through one-on-one meetings while also highlighting clinical and commercial progress in the field.

CIRM hosted its 2011 Grantee Meeting in San Francisco, bringing together the stem cell scientists and trainees that the institute is funding. This leading ed...

With age, cells accumulate stochastic and programmed changes to their DNA that can contribute to aging-associated cellular dysfunction, cancer or degenerative diseases. The impact of aging on endogenous adult stem cells or on induced pluripotent stem cells derived from adult tissues is poorly understood. This panel will address how genome changes brought on by age may impact stem cell function and genome stability. It will also address the challenges and opportunities for using pluripotent stem cells to model or treat aging associated diseases. Moderator: Adam Engler, Ph.D., Assistant Professor, Department of Bioengineering, UC San Diego Panelists: Irina Conboy, Ph.D., Associate Professor, Department of Bioengineering, UC Berkeley Eros Lazzerini Denchi, Ph.D., Assistant Professor, Department of Molecular & Experimental Medicine, The Scripps Research Institute Lawrence Goldstein, Ph.D., Distinguished Professor, Departments of Cellular & Molecular Medicine & Neurosciences; Director, UC San Diego Stem Cell Program; Scientific Director, Sanford Consortium for Regenerative Medicine

The sudden and tragic death of Duane Roth has deeply saddened everyone at CIRM. Duane was more than just a valued member of our governing board, he was also a good friend and someone who played a hugely important role in shaping the decisions we made. Duane died August 3rd from injuries sustained in a bicycling accident on July 21. With experience in the pharmaceutical, biotech and life sciences fields, and as a champion of technology entrepreneurship, Duane was uniquely qualified to help guide the stem cell agency's board in its policy and decision making. The CIRM board held a tribute to Roth during its August 28th 2013 meeting which included a viewing of the video above. To formally honor him, CIRM chair Jonathan Thomas announced the renaming of an upcoming RFA to the Duane Roth Disease Team Therapy Development IV award. In addition, a lecture series at the annual Meeting on the Mesa will carry his name. Duane was a big supporter of Pedal the Cause, an organization that raises funds for cancer research. Donations can be made to the organization in Roth's name.

La formacin de la prxima generacin de cientficos expertos en la investigacion con clulas madre es una misin importante para la Agencia de Clulas Madre de California (CIRM). Este video cuenta con Jazmin Penado, una estudiante senior (2014) en Balboa High School en San Francisco, que pas el verano pasado como becaria de CIRM investigando con clulas madre durante una estancia interna de investigacin en el laboratorio de Barbara Panning en el Campus Mission Bay de UCSF. A lo largo de los tres aos de este programa de premios Creatividad CIRM, la agencia ha financiado a 220 estudiantes de educacin secundaria para hacer estancias internas investigando con clulas madre. Para obtener ms informacin, visite nuestro sitio web: http://www.cirm.ca.gov/2013-creativity ===== Training the next generation of stem cell scientists is an important mission for California's Stem Cell Agency (CIRM). This video features Jazmin Penado, a 2014 senior at Balboa High School in San Francisco, who spent this past summer as a CIRM-funded stem cell research intern in the lab of Barbara Panning at UCSF's Mission Bay Campus. Over the course of this three-year CIRM Creativity Awards program, the agency will have supported 220 high school students in stem cell research internships. For more information, visit our website: http://www.cirm.ca.gov/2013-creativity

Pursuing his significant interest in non-embryonic stem cell research, Governor Perry visited the Loring Laboratory at Scripps Research in San Diego. San Die...

Read the original here:
UTSA hosts RegenMed conference on stem cell research ...

Manchester UK (PRWEB UK) 10 February 2014

RegenX Content The content posted on RegenX is generated through Dr. Stephen Richardson and a number of other stem cell experts in a collaborative effort between Brickhouse Publications and the University of Manchester. Dr. Richardson's 10 years of experience working with adult stem cells, coupled with the expertise of top-notch scientists, provides website visitors with the most current research information. The website is designed for people of all ages to read and comprehend, making it truly accessible to all.

In order to break down the complex concepts about stem cells and regenerative medicine, the website was designed with many visuals to aid in understanding. For those who learn best through reading text, there are many articles and informational bits. In addition, there are also many short animations, including a spoof news video, to help the general public understand the science behind research.

As far as the different topics are concerned, RegenX presents visitors with a wide range of information, building up from the simple to the complex. Some information simply shares the basics around stem cell and regenerative medicine research, while other pieces delve into more technical details. There are even informational pieces available that discuss the ethics around stem cell research, specifically. There is even a stem cell quiz on the website so readers can take to see where they stand on their understanding of the research and use.

Out in the general public, there is not very much accurate information shared about stem cell and regenerative medicine research. The media does not help as it often mis-portrays the benefits. Most often, the mis-portrayals lie in the legality and morality of the issue. Unfortunately, the misunderstood issues surrounding stem cell research can be huge roadblocks for those trying to advance the science around it.

Educational Outreach In order to address some of the misunderstandings about stem cell research, RegenX provides teacher packs that complement the site. These packets can be used in schools, colleges, and universities, to help educate the public. The classroom activities presented are usually animated or in video format, making it more engaging and easy to understand. In addition to helping students learn, the videos also help classroom teachers who are lacking the information to build some background knowledge. The teacher packets also include debate and discussion topics for students to process the information.

Included in the teacher packets from RegenX are interviews with stem cell research experts. Their information is research-based as they all work at the University of Manchester. In addition to discussing stem cell and regenerative medicine, the experts also share information about the jobs and the research currently conducted at the University. They even talk about their careers and what they needed to do in order to earn the privilege of conducting such research.

Funding The RegenX website is funded with monies from the Biotechnology and Biological Sciences Research Council (BBSRC) and the University of Manchester. Their reason for funding the project was to offer unbiased, scientifically accurate information for people from a variety of backgrounds. Their intended audience is not purely scientists, but also children and adults of all ages from all walks of life.

Staying Updated In order to keep people updated in a fast-changing field, the website has Facebook and Twitter pages to complement it. These social media networks allow RegenX to relay a great deal of updated information in a quick way. They are also able to reach a larger population of readers at any time of the day to keep them posted as well.

Making sure that people are getting the most updated information as quickly as possible is one way to build a community, which was the initial goal of Dr. Stephen Richardson. He wanted to make sure that there was a community of individuals who have slight or intense interest in stem cell and regenerative medicine research. It is also healthy to generate debate around the latest information in the field.

More:
Ground Breaking New Website REGENX, provides credible and up to date information on Stem Cell research straight from ...

(PRWEB) February 11, 2014

The report Autologous Cell Therapy (ACT) Market (2012 - 2017), would be the first global and exclusive report on ACT market. It also gives clear information about the complete industry, approved products and potential market size; it also identifies driving and restraining factors for the global ACT market with analysis of trends, opportunities and challenges. The market is segmented and revenue is forecasted on the basis of major regions such as USA, Europe and Rest of the World (ROW). Further, market is segmented and revenues are forecasted on the basis of potential application areas of ACT.

Browse ACT market research data tables/figures spread through 111 slides and in-depth TOC on Autologous Cell Therapy Market". http://www.marketsandmarkets.com/Market-Reports/autologous-cell-therapy-market-837.html

Early buyers will receive 10% customization on this report @ http://www.marketsandmarkets.com/requestCustomization.asp?id=837.

The global market for ACT is valued around $650 million by 2011 with a CAGR of 21%. Several products and technologies of ACT are in pipeline which is expected to hit the market during the forecast period, which will result in increased growth rate.

There is a wide market potential and favorable landscape for adoption across many geographical locations of the world. During the forecast period, these technologies are expected to revolutionize the area of bio-pharma and personalized medicine. High incidence and lack of effective treatment for several diseases will drive the ACT technology in developed and developing nations.

Investment activities, for the past five years are actively held in research and developments, attracting interests of cell therapy industry firms, medical centers and academic institutions. ACT potential can be demonstrated by mergers, collaborations, acquisitions and partnerships that happened actively between the ACT technology developing companies in past three years. Development of sophisticated automation devices for cell expansion and culture process for use in the treatment is one of the emerging trends of ACT market.

Autologous Stem Cell and Non-Stem Cell Based treatments in North America are rapidly emerging as a major treatment for various incurable diseases such as Myocardial infarction, ischemic heart failure and diabetes.

Browse Related Reports: Global Transfection Technologies Market (Lipofection, Calcium Phosphate, Electroporation, Nucleofection, Magnetofection, Gene Gun, Viral) And Types (Gene Delivery, DNA Delivery, Protein Delivery, SiRNA Delivery) (2012 2017) http://www.marketsandmarkets.com/Market-Reports/transfection-technologies-market-895.html

High Throughput Screening (HTS) Market by Technology (Cell Based, Ultra High Throughput Screening (uHTS), Label Free, Bioinformatics), by Apllications (Target Identification, Primary Screening, Toxicology, Stem Cell) & by End Users (Pharmaceutical Industry, Biotechnology Industry, CRO) - Forecast to 2018 http://www.marketsandmarkets.com/Market-Reports/high-throughput-screening-market-134981950.html

Read more:
Autologous Stem Cell and Non-Stem Cell Based Therapies Market Worth $2.2 Billion by 2017

Random Compilation 26 - ft: bikers close call, stem cells and a gold plated double decker
In this RC: slippery, where does it begin, the genesis of traffic, stem cells will cure it all, truck fun, the bigger the better, shiiiiiiiiiiiiiiiiii*

By: BikersPOV

Read the original here:
Random Compilation 26 - ft: bikers close call, stem cells and a gold plated double decker - Video

Stem cell therapy - Age reversal1 - Cristal Jan 2014
http://a1stemcells.com/ Cristal, 70 years old. 1 Year after our 1st Age reversal study with stem cells (12 ESC injections in 12 months) For more info: http:/...

By: A1 Stem Cells

More here:
Stem cell therapy - Age reversal1 - Cristal Jan 2014 - Video

Enlarge

Noah Berger

Stem cells are shown through a microscope in a research lab at the Gladstone Institute of Cardiovascular Disease in San Francisco.

The regions leading stem cell and regenerative medicine researchers and business people will gather this week for a conference at the University of Texas at San Antonio.

The fist San Antonio Conference on Stem Cell Research and Regenerative Medicine will begin at 8 a.m. on Feb. 13 with opening remarks from UTSA President Ricardo Romo and former San Antonio Mayor Henry Cisneros.

Dr. J. Peter Rubin from the McGowan Institute of Regenerative Medicine will deliver the keynote address.

The two-day conference has been organized by local nonprofit RegenMed SA to promote the stem cell and regenerative medicine research underway in San Antonio.

In December, San Antonio will host the World Stem Cell Summit, the largest interdisciplinary stem cell meeting of its kind featuring more than 170 prominent scientists, business leaders, regulators, policy-makers and other experts.

See the original post:
UTSA sponsoring conference on stem cell research - San ...

f This is how a living, beating heart is grown from stem cells
. This is how a living, beating heart is grown from stem cells.

By: saddam dz

See more here:
f This is how a living, beating heart is grown from stem cells - Video

Obtaining human embryonic stem cells thru #39; therapeutic cloning
Obtaining human embryonic stem cells through the process of therapeutic cloning has important applications in science and medicine.Shoukhrat Mitalipov #39;s team...

By: bbvaopenmind

Read the original post:
Obtaining human embryonic stem cells thru' therapeutic cloning - Video

Already, scientists in laboratories across the world have begun dipping mature cells in acid, hoping to see whether this simple intervention really can trigger a transformation into stem cells, as reported by a team of Boston and Japanese researchers last week.

At the Harvard Stem Cell Institute, a number of scientists have already embarked on the experiment, which theyre informally calling stem cell ceviche, comparing it to the Latin American method of cooking seafood in lime and lemon juice. At meetings with other experts and even in casual conversation, stem cell scientists say they are exchanging surprise, doubt, and wonder about the discovery, reported in two papers in the journal Nature.

The range of responses varies widely. But most scientists seem to be surprised and skeptical about the technique, though also impressed by the rigorous testing that experts in the field did on the cells. It appears that no one knows quite what to think.

Paul Knoepfler, an associate professor in the department of cell biology and human anatomy at the University of California, Davis, has been blogging extensively about the discovery and polled his readers about what they think. In an unscientific poll that has drawn about 400 responses, hes found that scientists are pretty evenly split on whether they are leaning toward believing in the technique or not. Interestingly, he found people responding to the poll from Japan are far more likely to be convinced it is true.

On Thursday, Knoepfler made his own opinion known. Its a harsh critique, starting with his view that the method is illogical and defies common sense. It ends with questions about why the researchers would only now be trying the technique on human cells, since they seemed to have proved it to themselves for several years now. The biggest mystery may be why, if simple stress can trigger cells to return to a stem cell-like state, it doesnt happen more often in the body. Why dont people just have lots of cancers and tumors in the acidic environment of their stomach, for example?

There are also basic questions about whether these truly are the same as spore-like cells that Dr. Charles Vacanti, an anesthesiologist at Brigham and Womens Hospital who led the new work, described in a highly controversial 2001 paper. Many scientists doubted the existence of those cells, and Vacanti has said he thinks the new stem cells, which are called STAP cells, are the same.

Obviously, it has to be reproduced. Thats the caveat, said Dr. Kenneth Chien, a professor in the department of cell and molecular biology and medicine at the Karolinska Institute in Stockholm. I still think its shocking. And it makes me wonder if its true or not, its so shocking.

Right now, we seem to have arrived at an unusual spot in scienceno one knows quite what to believe. People have quite informed gut reactions, but still seem to lack solid evidence to show the technique does or doesnt hold up. Its exciting and nerve wracking, but even those with doubts dont seem ready to dismiss it outright. This is how science works: people turn to the experiments to smash or solidify their doubts. Many are scurrying to recreate those in their laboratories, which should bring some clarity to the situation.

One reason the finding is so unusual is that it pretty much blind-sided the scientific community. Often, researchers are aware of discoveries that will be published in their fields through informal channels. They attend the same meetings, they present early versions of their results, or they know who is generally working on what area of research. In this case, people were surprised. Thats in part because one of the scientists pushing the work was far from an insider. Vacanti is an anesthesiologist, not a stem cell scientist.

Notably, even though the team of researchers was partially based in Boston, where there are many leaders in the stem cell field, they turned to world experts in Japan to vet the cells.

See the original post here:
The debate over new stem cell technique begins - Boston.com

MediVet Stem Cell Therapy For Pets
MediVet is the company that created the technology to use stem cell therapy to treat pets with arthritis and hip dysplasia.

By: Newman Veterinary Centers

View original post here:
MediVet Stem Cell Therapy For Pets - Video

In Vivo Differentiation Potential of Epiblast Stem Cells Revealed by Chimeric Embryo Formation
The ability of embryonic stem cells (ESCs) to form chimeric mice when injected into pre-implantation blastocysts is considered the #39;gold standard #39; assay that definitively proves that ESCs are...

By: CRMedinburgh

The rest is here:
In Vivo Differentiation Potential of Epiblast Stem Cells Revealed by Chimeric Embryo Formation - Video

Dr. Nathan Newman - The Power of Stem Cells Technology
The Power of Stem Cells Technology Click on the link below for more details http://www.generation-young.eu.

By: Generation Young

View original post here:
Dr. Nathan Newman - The Power of Stem Cells Technology - Video

Stem Cells in Facioscapuloumeral Muscular Dystrophy research
Dr. Gabsang Lee of Johns Hopkins Medical School speaks about human induced pluripotent stem cell research at the FSH Society #39;s Mid-Atlantic Patient Meeting, ...

By: FSH Society

Read this article:
Stem Cells in Facioscapuloumeral Muscular Dystrophy research - Video

Poway, CA (PRWEB) February 06, 2014

Stem Cell Therapy for Feline Kidney Disease is a special interest piece produced by Nicky Sims, the owner of Kitters, who recently had Vet-Stem Regenerative Cell Therapy for his Feline Kidney Disease. Nicky highlights Kitters journey through diagnosis of the disease and his recent stem cell therapy, as well as educating about stem cells and their benefits.

Nickys film explains that Kitters began showing signs of kidney failure at the age of 15, exhibiting classic symptoms; lack of appetite, excessive thirst, nausea and lethargy. In 2012, Kitters was officially diagnosed with Chronic Renal Failure, or kidney disease. He was prescribed a low protein diet and subcutaneous fluids for rehydration. This has been the standard treatment for decades although it has only been shown to slow the progression of the disease; not reverse it.

Dr. Richter at Montclair Veterinary Hospital thinks that there is something else that can help. In recent years, his hospital has begun using stem cells to treat animals for various orthopedic conditions such as pain from arthritis and dysplasia. In October 2013, Kitters would be the first cat he had treated with stem cell therapy for Feline Kidney Disease.

Dr. Richter explains why this could work for Kitters, Stem cells are cells within your body that are able to turn into any other cell in the body. Kitters has kidney issues, so what weve done is harvested some fat from his abdomen and sent that fat to Vet-Stem in San Diego, and what they do is isolate the stem cells from the fatty tissue. They concentrate them and send them back to us. In the case of an animal with kidney disease, we just give the stem cells intravenously. What that is going to do is begin the healing and rebuilding process.

Nickys film explores the importance of kidneys stating they play a vital role, ridding the body of toxins. As kidney disease progresses scar tissue develops making it harder to filter toxins. Damage to the kidneys makes the animal vulnerable to a number of other health conditions. Unfortunately the disease usually goes undiagnosed given that the symptoms of the disease often do not show until 2/3 of the kidneys are damaged.

Kitters own stem cells were used with the hope of repairing his damaged tissue Dr. Richter goes on, The nice thing about stem cells is that there is no issue of tissue rejection, since it is Kitters own stem cells. Additionally, if there is anything else going on in his body beyond the kidneys its going to address that as well. So, it is a really wonderful systemic treatment.

To find out more or view the special interest piece by Nicky Sims, Stem Cell Therapy for Feline Kidney Disease, visit this link.

About Vet-Stem, Inc. Vet-Stem, Inc. was formed in 2002 to bring regenerative medicine to the veterinary profession. The privately held company is working to develop therapies in veterinary medicine that apply regenerative technologies while utilizing the natural healing properties inherent in all animals. As the first company in the United States to provide an adipose-derived stem cell service to veterinarians for their patients, Vet-Stem, Inc. pioneered the use of regenerative stem cells in veterinary medicine. The company holds exclusive licenses to over 50 patents including world-wide veterinary rights for use of adipose derived stem cells. In the last decade over 10,000 animals have been treated using Vet-Stem, Inc.s services, and Vet-Stem is actively investigating stem cell therapy for immune-mediated and inflammatory disease, as well as organ disease and failure. For more on Vet-Stem, Inc. and Veterinary Regenerative Medicine visit http://www.vet-stem.com or call 858-748-2004.

Go here to see the original:
Stem Cell Therapy for Feline Kidney Disease, a Video Testimonial by a Pleased Pet Owner Gives Hope for Cats Suffering ...

Miami (PRWEB) February 05, 2014

Global Stem Cells Group, Inc. and BioHeart, Inc. announce the launch of a clinical trial for the treatment of Chronic Obstructive Pulmonary Disease (COPD) using adipose-derived stem cell technology. The clinical trials will be held at the Global Stem Cells treatment center in Cozumel, Mexico, as well as in several U.S. states. Global Stem Cells Group affiliate Regenestem in collaboration with CMC Hospital of Cozumel offer cutting-edge cellular medicine treatments to patients from around the world

The study titled "An Open-label, Non-Randomized, Multi-Center Study to Assess the Safety and Effects of Autologous Adipose-Derived Stromal Cells Delivered intravenously in Patients with Chronic Obstructive Pulmonary Disease" is lead by principal investigator Armando Pineda Velez, Global Stem Cells Group Medical Director. Global Stem Cells Group has represented that it offers the most advanced protocols and techniques in cellular medicine from around the world.

The Cozumel clinical trials will be lead by Rafael Moguel, M.D., an advocate and pioneer in the use of stem cell therapies to treat a wide variety of conditions.

COPD is one of more than 150 chronic conditions that are treatable with adult stem cells, eliminating the potential risk of surgery, transplants, and toxic drugs

Details of the protocol and eligibility criteria can be found on the government clinical trial website at: http://www.clinicaltrials.gov.

For more information on Global Stems Cell Group, visit the Global Stem Cells Group website, email bnovas(at)regenestem(dot)com, or call 305-224-1858.

About Global Stem Cells Group:

Global Stem Cells Group, Inc. is the parent company of six wholly owned operating companies dedicated entirely to stem cell research, training, products and solutions. Founded in 2012, the company combines dedicated researchers, physician and patient educators and solution providers with the shared goal of meeting the growing worldwide need for leading edge stem cell treatments and solutions.

With a singular focus on this exciting new area of medical research, Global Stem Cells Group and its subsidiaries are uniquely positioned to become global leaders in cellular medicine.

More:
Global Stem Cells Group, Inc. and BioHeart, Inc. Launch Clinical Trial for COPD Stem Cell Therapies